Alira Health’s Take on the EMA DCT Guidance

Last week the European Medicines Agency (EMA) published their “Recommendation Paper on Decentralised Elements in Clinical Trials”, providing guidance on new virtual methods in clinical trials that are rapidly gaining in popularity. Decentralized clinical trials involve the use of remote or virtual technologies to conduct clinical research and have the potential to increase access to clinical trials for both patients and investigators by reducing cost, increasing convenience, and reaching a more diverse pool of participants.

Publications
Published on:
December 19, 2022
Written by:
Jared Adams, MD, PhD
Above all, the Recommendation Paper advises that the patient perspective should guide decentralized protocol development and the benefit-risk calculation of decentralized elements such that 'the rights, safety, dignity and well-being of the trial participants should be protected and prevail over all other interests.'"
Jared Adams, MD, PhD Senior Vice President, Product Management and Design

Paper Summary – The Patient Perspective is Paramount

The Recommendation Paper provides guidance on the design and conduct of decentralized clinical trials. It covers a range of topics, including the use of electronic informed consent, remote monitoring and data collection, stakeholder responsibilities and risk mitigation strategies. Concerns that must be addressed at the protocol stage include questions of generalizability, validity, and handling of missing data. Utilizing multiple systems and parties adds complexity and requires additional oversight. Overall, the recommendation paper emphasizes the importance of ensuring the quality, integrity, and reliability of decentralized clinical trials and provides guidance on how to achieve these goals through the careful consideration of appropriate technologies and protocols.

Above all, the Recommendation Paper advises that the patient perspective should guide decentralized protocol development and the benefit-risk calculation of decentralized elements such that “the rights, safety, dignity and well-being of the trial participants should be protected and prevail over all other interests.”

Alira Health’s Health Storylines – Putting Patients at the Center

At Alira Health, we offer a single patient driven “product lifecycle research platform” in Health Storylines that follows the product from early phase clinical trials to post-marketing and the patient along the entire patient journey until there is patient impact. As a leader in decentralized clinical trials, Alira Health can help stakeholders carefully evaluate the feasibility and suitability of decentralized approaches for a specific trial, and to ensure that appropriate safeguards are in place to mitigate any potential risks.

Related news

Publications July 11, 2023
Mid-size Pharma Accelerates Early Clinical Trial Engagement of Patients with A Rare Neurological Disease
A mid-size pharma company sought an experienced advisor who could help them engage patients for an open-label extension clinical study in a rare neurological disease.
Clinical Trials Patient Engagement Pharma Rare Disease
Events June 20, 2023
Advanced Wound Care Summit
We are pleased to announce that we will sponsor, attend, and speak at Advanced Wound Care Summit.
Clinical Clinical Trials Wound Healing
Events June 16, 2023
In Silico Modeling in Healthcare
We are excited to co-organize this unique event that will bring together key industry stakeholders to discuss the future of in silico modeling in healthcare.
Biopharma Clinical Trials Pharma Research and Development
Events June 16, 2023
Revitalize Summit
Our speaker, Estefi Alvarez, will join the panel “Reimbursement pathways for FemHealth Innovations" at the Revitalize Online Summit.
Clinical Trials MedTech
Blog June 12, 2023
Recruitment Challenges in Clinical Studies and How to Overcome Them
Gain insight from our experts on clinical study recruitment challenges as well as a wide array of solutions for overcoming them.
Clinical Trials Patient Engagement
News May 22, 2023
Alira Health Joins France Biotech as an Expert Partner
We are pleased to announce that Alira Health has joined France Biotech, an independent association that brings together healthcare innovation entrepreneurs and their expert partners.
Biotech Clinical Trials France Patient Engagement
Multimedia May 17, 2023
How to Increase Patient Engagement in Your Clinical Trials
Engaging with patients, including their caregivers and advocates, is crucial during the planning and execution of clinical trials.
Clinical Trials Patient Engagement
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.